Karim H. Saba

Karim H. Saba

Auto-generated profile, based on publicly available information

Karim H. Saba

Lund University

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 February 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
CSCarl Sandén
Carl Sandén
HLHenrik Lilljebjörn
Henrik Lilljebjörn
CPChristina Orsmark Pietras
Christina Orsmark Pietras
RHRasmus Henningsson
Rasmus Henningsson
KSKarim H. Saba
Karim H. Saba
TFThoas Fioretos
Thoas Fioretos
Clonal heterogeneity and evolution has major implications for disease progression and relapse in acute myeloid leukemia (AML). To model clonal dynamics in vivo, we serially transplanted 23 AML cases to immunodeficient mice and followed clonal composition for up to 15 months by whole-exome sequencing of 84 xenografts across two generations. We demonstrate vast changes in clonality that both progress and reverse over time, and define five patterns of clonal dynamics: Monoclonal, Stable, Loss, Expansion and Burst. We also show that subclonal expansion in vivo correlates with a more adverse prognosis. Furthermore, clonal expansion enabled detection of very rare clones with AML driver mutations that were undetectable by sequencing at diagnosis, demonstrating that the vast majority of AML cases harbor multiple clones already at diagnosis. Finally, the rise and fall of related clones enabled deconstruction of the complex evolutionary hierarchies of the clones that compete to shape AML over time.

5 February 2020 in The Journal of Pathology: Clinical Research
Verified
Journal Article
Open access
PDF file
BABaptiste Ameline
Baptiste Ameline
KSKarim H Saba
Karim H Saba
MKMichal Kovac
Michal Kovac
LMLinda Magnusson
Linda Magnusson
OWOlaf Witt
Olaf Witt
DBDaniel Baumhoer
Daniel Baumhoer
Neurotrophic tyrosine receptor kinase (NTRK) fusions are promising molecular targets that have been described in a broad range of malignant tumours. Fusions commonly lead to the expression of chimeric proteins with constitutive tyrosine kinase activation that drives tumorigenesis. Despite a low prevalence among most solid tumours (<1%), the first encouraging results with pan‐NTRK tyrosine kinase inhibitors (TKIs) such as larotrectinib or entrectinib stimulated the search for eligible patients. Here, we report the first three cases of osteosarcoma harbouring NTRK fusions, among 113 patients sequenced. It is also the first report on NTRK fusions within a tumour type characterised by highly rearranged genomes and abundant passenger mutations. Whereas the presence of NTRK gene fusions in many tumours is considered to be one of the main driver events for tumour progression, the three chimeric transcripts described here appear non‐functional and likely represent randomly occurring passenger alterations. Particularly in tumours with complex karyotypes, it may therefore be advisable to specifically investigate the fusion transcripts for functional impact before considering targeted treatment approaches using pan‐NTRK TKIs.

27 November 2023 in The Journal of Pathology
Verified
Journal Article
Open access
KSKarim H Saba
Karim H Saba
VDValeria Difilippo
Valeria Difilippo
MKMichal Kovac
Michal Kovac
LCLouise Cornmark
Louise Cornmark
LMLinda Magnusson
Linda Magnusson
KNKarolin H Nord
Karolin H Nord
TP53 is the most frequently mutated gene in human cancer. This gene shows not only loss‐of‐function mutations but also recurrent missense mutations with gain‐of‐function activity. We have studied the primary bone malignancy osteosarcoma, which harbours one of the most rearranged genomes of all cancers. This is odd since it primarily affects children and adolescents who have not lived the long life thought necessary to accumulate massive numbers of mutations. In osteosarcoma, TP53 is often disrupted by structural variants. Here, we show through combined whole‐genome and transcriptome analyses of 148 osteosarcomas that TP53 structural variants commonly result in loss of coding parts of the gene while simultaneously preserving and relocating the promoter region. The transferred TP53 promoter region is fused to genes previously implicated in cancer development. Paradoxically, these erroneously upregulated genes are significantly associated with the TP53 signalling pathway itself. This suggests that while the classical tumour suppressor activities of TP53 are lost, certain parts of the TP53 signalling pathway that are necessary for cancer cell survival and proliferation are retained. In line with this, our data suggest that transposition of the TP53 promoter is an early event that allows for a new normal state of genome‐wide rearrangements in osteosarcoma. © 2023 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.

8 May 2019 in Genes, Chromosomes and Cancer
Verified
Journal Article
Closed access
PDF file
KSKarim H. Saba
Karim H. Saba
LCLouise Cornmark
Louise Cornmark
MRMarianne Rissler
Marianne Rissler
TFThoas Fioretos
Thoas Fioretos
KÅKristina Åström
Kristina Åström
KNKarolin H. Nord
Karolin H. Nord

30 September 2022 in Genes, Chromosomes and Cancer
Verified
Journal Article
Open access
NANatalie Andersson
Natalie Andersson
KSKarim H. Saba
Karim H. Saba
LMLinda Magnusson
Linda Magnusson
JNJenny Nilsson
Jenny Nilsson
JKJenny Karlsson
Jenny Karlsson
DGDavid Gisselsson
David Gisselsson
Chromosomal instability is a common feature in malignant tumors. Previous studies have indicated that inactivation of the classical tumor suppressor genes RB1, CDKN2A, and TP53 may contribute to chromosomal aberrations in cancer by disrupting different aspects of the cell cycle and DNA damage checkpoint machinery. We performed a side-by-side comparison of how inactivation of each of these genes affected chromosomal stability in vitro. Using CRISPR-Cas9 technology, RB1, CDKN2A, and TP53 were independently knocked out in karyotypically normal immortalized cells, after which these cells were followed over time. Bulk RNA sequencing revealed a distinct phenotype with upregulation of pathways related to cell cycle control and proliferation in all three knockouts. Surprisingly, the RB1 and CDKN2A knocked out cell lines did not harbor more copy number aberrations than wild-type cells, despite culturing for months. The TP53-knocked out cells, in contrast, showed a massive amount of copy number alterations and saltatory evolution through whole genome duplication. This side-by-side comparison indicated that the effects on chromosomal stability from inactivation of RB1 and CDKN2A are negligible compared to inactivation of TP53, under the same conditions in a nonstressful environment, even though partly overlapping regulatory pathways are affected. Our data suggest that loss of RB1 and CDKN2A alone is not enough to trigger surviving detectable aneuploid clones while inactivation of TP53 on its own caused massive CIN leading to saltatory clonal evolution in vitro and clonal selection.

16 June 2020 in The Journal of Pathology: Clinical Research
Verified
Journal Article
Open access
PDF file
KSKarim H Saba
Karim H Saba
LCLouise Cornmark
Louise Cornmark
JHJakob Hofvander
Jakob Hofvander
LMLinda Magnusson
Linda Magnusson
JNJenny Nilsson
Jenny Nilsson
KNKarolin H Nord
Karolin H Nord
Osteoblastoma is a locally aggressive tumour of bone. Until recently, its underlying genetic features were largely unknown. During the past two years, reports have demonstrated that acquired structural variations affect the transcription factor FOS in a high proportion of cases. These rearrangements modify the terminal exon of the gene and are believed to stabilise both the FOS transcript and the encoded protein, resulting in high expression levels. Here, we applied in‐depth genetic analyses to a series of 29 osteoblastomas, including five classified as epithelioid osteoblastoma. We found recurrent homozygous deletions of the NF2 gene in three of the five epithelioid cases and in one conventional osteoblastoma. These events were mutually exclusive from FOS mutations. Structural variations were determined by deep whole genome sequencing and the number of FOS‐rearranged cases was less than previously reported (10/23, 43%). One conventional osteoblastoma displayed a novel mechanism of FOS upregulation; bringing the entire FOS gene under the control of the WNT5A enhancer that is itself activated by FOS. Taken together, we show that NF2 loss characterises a subgroup of osteoblastomas, distinct from FOS‐rearranged cases. Both NF2 and FOS are involved in regulating bone homeostasis, thereby providing a mechanistic link to the excessive bone growth of osteoblastoma.